Bridgeway Capital Management’s Spero Therapeutics SPRO Stock Holding History

Bridgeway Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254K	Hold	114,800	–	–	﹤0.01%	1009
2026 Q1	$269K	Hold	114,800	–	–	0.01%	960
2025 Q4	$267K	Hold	114,800	–	–	0.01%	960
2025 Q3	$216K	Hold	114,800	–	–	﹤0.01%	1001
2025 Q2	$333K	Sell	114,800 -40,000	-26%	-$57.5K	0.01%	847
2025 Q1	$111K	Sell	154,800 -30,000	-16%	-$25.3K	﹤0.01%	1019
2024 Q4	$190K	Hold	184,800	–	–	﹤0.01%	1022
2024 Q3	$248K	Hold	184,800	–	–	0.01%	1012
2024 Q2	$240K	Hold	184,800	–	–	0.01%	1014
2024 Q1	$318K	Buy	184,800 +50,000	+37%	+$78.4K	0.01%	1026
2023 Q4	$198K	Hold	134,800	–	–	﹤0.01%	1135
2023 Q3	$163K	Buy	134,800 +25,000	+23%	+$34.6K	﹤0.01%	1134
2023 Q2	$159K	Hold	109,800	–	–	﹤0.01%	1180
2023 Q1	$159K	Buy	+109,800	New	+$184K	﹤0.01%	1144
2020 Q2	–	Sell	-69,305	Closed	-$560K	–	1393
2020 Q1	$560K	Sell	69,305 -1,274	-2%	-$11.2K	0.01%	729
2019 Q4	$679K	Buy	70,579 +16,000	+29%	+$173K	0.01%	845
2019 Q3	$579K	Hold	54,579	–	–	0.01%	889
2019 Q2	$628K	Hold	54,579	–	–	0.01%	901
2019 Q1	$699K	Buy	54,579 +26,000	+91%	+$276K	0.01%	893
2018 Q4	$176K	Sell	28,579 -50,000	-64%	-$405K	﹤0.01%	1236
2018 Q3	$826K	Buy	78,579 +23,879	+44%	+$277K	0.01%	976
2018 Q2	$802K	Hold	54,700	–	–	0.01%	961
2018 Q1	$779K	Buy	+54,700	New	+$663K	0.01%	930

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bridgeway Capital Management's SPRO Position: Q2 2026 in Review

Bridgeway Capital Management held its Spero Therapeutics (SPRO) position steady in Q2 2026 at 114,800 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #1009.

Bridgeway Capital Management first reported a position in SPRO in Q1 2018 and has held it in 23 quarters since. The position peaked at $826K in Q3 2018. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Bridgeway Capital Management held 114,800 shares of Spero Therapeutics worth $254K as of Q2 2026.
Bridgeway Capital Management left its Spero Therapeutics share count unchanged in Q2 2026.
Spero Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1009 holding.
Bridgeway Capital Management first reported a position in Spero Therapeutics in Q1 2018 and has held it in 23 quarters since.
Bridgeway Capital Management's Spero Therapeutics position peaked at $826K in Q3 2018.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.